BRCA2 mutation involves a lifetime risk of developing PC ranging from 30-40%, while BRCA1 mutation carriers present a 3–8% lifetime risk with a modestly elevated incidence of early onset prostate cancer but no increased risk in older men (38). The gene discussed is BRCA1; the disease is prostate cancer.